Report outlines 17 targeted actions to address structural barriers hindering leadership progression Copenhagen / Oslo / Stockholm, April 17, 2026 — The Nordic life science sector is losing highly qualified female talent in top leadership positions, according to a new white paper published by Women in Life Science Denmark (WiLD), WiLD Norway, and VILDA Sweden. […]
The proceeds will support the advancement of STC-15 in a Phase 2 study in select sarcoma indications First‑in‑class METTL3 inhibitor reprograms malignant progenitor cells by modulating mRNA methylation 16 April 2026, Cambridge, UK: STORM Therapeutics Ltd. (STORM), the clinical stage company targeting RNA modifications to reprogram cells and develop novel cancer therapies, today announced a […]
Trial on track to deliver interim data this summer 15 April 2026- Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces that the UK Medicines and Healthcare products Regulatory Agency (“MHRA”) has granted Clinical Trial Authorisation (“CTA”) for the POLB 001 TOPICAL trial. With all required […]
Investment firms The European Investment Fund (EIF) launched a new €15bn fund to back growth-stage investors across the continent Ysios Capital launched a €100m fund, InceptionBio, focused on biotech company creation and early-stage projects, with a strong focus on Spain Blackstone raised $6.3bn for its latest life sciences investment fund, Blackstone Life Sciences VI, to back late-stage development programs Breakout […]
Additional funding of €4m from new co-lead investor Biovance Capital, and €1.5m from existing co-lead Kurma Partners, to reach a total of €5.5m. Funds will be used to further develop Laigo’s SureTACs™ targeted protein degradation candidates in oncology and auto-immunity. UTRECHT, the Netherlands – 23 March 2026 – Laigo Bio (“Laigo”), a biotech company pioneering […]
